Magnera reported higher sales and adjusted EBITDA in the fourth quarter and fiscal year 2026, supported by pricing, cost savings and merger-related benefits. However, a US$106 million goodwill and other impairment charge contributed to an operating loss for the year.
For the fourth quarter ended September 26, 2026, net sales increased 1% to US$851 million, compared with US$839 million in the prior-year period. Adjusted EBITDA rose 8% to US$97 million from US$90 million.
The company reported a GAAP operating loss of US$90 million, compared with operating income of US$10 million in the fourth quarter of fiscal 2025. Net loss was US$141 million, against US$40 million a year earlier. The latest quarter included US$106 million in goodwill and other impairment charges.
For the full fiscal year, net sales increased 3% on a reported basis to US$3.30 billion, from US$3.20 billion. Excluding the effects of foreign currency and acquisitions, comparable sales declined 4%.
Adjusted EBITDA increased 7% to US$378 million, compared with US$354 million in fiscal 2025. On a comparable basis, the increase was 4%.
Magnera reported a full-year operating loss of US$37 million, compared with operating income of US$5 million in the previous year. Net loss widened to US$213 million from US$159 million.
Pricing offsets lower volumes
Fourth-quarter organic volumes declined 4% year over year, reflecting continued softness in several end markets. Higher selling prices contributed US$43 million to sales, including US$19 million in the Americas and US$24 million in Rest of World, primarily reflecting the pass-through of higher raw material costs.
In the Americas, fourth-quarter sales increased 3.4% to US$483 million, while organic volumes declined 2%. Adjusted EBITDA rose 7% to US$65 million from US$60 million.
Rest of World sales decreased 1.1% to US$368 million, with organic volumes down 6%. Adjusted EBITDA increased 10% to US$32 million, compared with US$30 million in the prior-year quarter.
The improvement in adjusted EBITDA was supported by a more favorable price-cost spread, which contributed US$9 million across the business, as well as Project CORE and merger-related benefits.
Management pointed to softer healthcare demand in the Americas and continued general market weakness in Europe. European order pushouts and customer inventory adjustments also affected volumes. The company said some recovery was becoming visible early in fiscal 2027, particularly in Rest of World.
Magnera also highlighted continued strength in wipes and infrastructure-related product lines, while noting that it had exited certain lower-margin business.
Cash generation and debt reduction
Operating cash flow increased to US$178 million in fiscal 2026, compared with US$103 million a year earlier.
Capital expenditures and net additions to property, plant and equipment totaled US$63 million, resulting in free cash flow of US$115 million, up from US$36 million in fiscal 2025.
Fourth-quarter cash from operations reached US$99 million.
Magnera repaid US$122 million of debt during the year, including US$57 million in the fourth quarter. On September 26, 2026, cash and cash equivalents stood at US$294 million, while total current and long-term debt amounted to US$1.85 billion, compared with US$1.95 billion a year earlier.
The company reported available liquidity of approximately US$600 million.
Project CORE and operational developments
Magnera said it had completed the second year of its initial three-year integration program. Management reported approximately US$45 million in benefits from actions implemented during fiscal 2026, with a further US$20 million in rollover benefits expected in fiscal 2027.
These figures relate to the relevant operational and cost actions and their carryover effects, rather than representing the entirety of the company's merger synergies.
The company also said it had delivered its merger synergy commitments to date, with further benefits expected in fiscal 2027. Project CORE is being developed into a broader business and operational excellence platform, alongside continued footprint and portfolio optimization.
Magnera completed the transition services agreement with Amcor on schedule, including the migration of 11 ERP systems across 10 manufacturing sites and one technical center.
The company also reported progress in product development. Its Innovation Vitality Index, which measures the contribution of newer products to the portfolio, reached nearly 30%, compared with 22% when the program began.
Recent developments include HighPleat advancement filtration media, food packaging applications drawing on the company's absorbency expertise, Universa industrial wipes, and improvements in personal care formulations and softness across adult, baby and feminine care products.
During the earnings call, management also provided an update on the Dombühl facility in Germany, where installation and commissioning of a new high-performance blown film line had been completed in October. Commercial production and shipments are expected to begin in the first quarter of calendar 2027.
Fiscal 2027 outlook
For fiscal 2027, Magnera expects adjusted EBITDA of US$390 million to US$410 million, representing approximately 6% comparable growth at constant currency at the midpoint.
The company expects operating cash flow of US$195 million to US$215 million and free cash flow of US$110 million to US$130 million. Capital expenditures are projected at approximately US$85 million, compared with US$63 million in fiscal 2026.
Management expects volumes in the Americas to grow at a low-single-digit rate, while Rest of World volumes are projected to be slightly negative to approximately flat. Overall, the company expects volumes to be broadly flat to slightly positive.
The outlook incorporates approximately US$10 million of European energy cost inflation. Management said around 70% of its European energy requirements for calendar 2027 had been hedged.
Magnera expects to use essentially all its anticipated free cash flow at the midpoint of guidance, approximately US$120 million, for debt repayment. The company is targeting leverage of around 3.6 times by the end of fiscal 2027, with a longer-term goal of 3.0 times.